Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Business

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales. 

Read the original report.

Articles You May Like

American Express is cutting 5% of its workforce to ‘prepare for AI’
Don’t Be Sold On A Medicare Plan: Go Shopping!
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Robinhood shares fall as crypto slump weighs on profits, offsetting gains in new businesses
Fed leaves rates unchanged: What it means for credit cards, mortgages, auto loans and savings accounts

Leave a Reply

Your email address will not be published. Required fields are marked *